Hochrisiko-Nierenzellkarzinom nach Operation

Nierenzellkarzinom mit intermediären oder hohem Risikoprofil

Efficacy and Safety of Pembrolizumab in Combination with Belzutifan Versus Pembrolizumab and Placebo for the Treatment of Participants with intermediate-high risk Clear Cell Renal Cell Carcinoma (ccRCC) Post Nephrectomy in the Adjuvant Treatment

Ausführliche Informationen



Metastasiertes Nierenzellkarzinom

Metastasiertes klarzelliges Nierenzellkarzinom
ccRCC Monotherapie XL-092

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen


Metastasiertes, nicht-klarzelliges Nierenzellkarzinom
nccRCC
Monotherapie XL-092

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen


Metastasiertes, nicht klarzelliges Nierenzellkarzinom
nccRCC
XL-092 und Immuntherapie

A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XL092 as Single-Agent and Combination Therapy in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors

Ausführliche Informationen